Related Experiment Video
Updated: Jul 7, 2026

08:45
Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors
Published on: July 17, 2020
Hepatoblastoma in a Noonan syndrome patient with a PTPN11 mutation
Rie Yoshida1, Tsutomu Ogata, Nobuhide Masawa
1Department of Endocrinology and Metabolism, National Research Institute for Child Health and Development, Tokyo, Japan.
Pediatric Blood & Cancer
|February 7, 2008
Abstract:
Although Noonan syndrome (NS) is occasionally associated with embryonal solid tumors, there has been no report of hepatoblastoma in NS. We identified hepatoblastoma spreading into bilateral hepatic lobes in a 1-month-old NS patient with a heterozygous PTPN11 mutation (Asn308Asp). This finding suggests the potential relevance of constitutively activated RAS/MAPK signaling in the development of hepatoblastoma.
